Compare INNV & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | ATAI |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2025 |
| Metric | INNV | ATAI |
|---|---|---|
| Price | $8.07 | $4.12 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $15.88 |
| AVG Volume (30 Days) | 216.1K | ★ 6.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $853,699,000.00 | $4,089,000.00 |
| Revenue This Year | $12.85 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | $58.86 | ★ N/A |
| Revenue Growth | 11.76 | ★ 1227.60 |
| 52 Week Low | $2.84 | $1.29 |
| 52 Week High | $10.69 | $6.73 |
| Indicator | INNV | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 50.13 |
| Support Level | $7.57 | $4.05 |
| Resistance Level | $8.63 | $4.30 |
| Average True Range (ATR) | 0.33 | 0.34 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 50.89 | 28.28 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.